



Munich, February 6th, 2023
FerroSens GmbH

FerroSens’ FIDscreen prototype devices successfully applied in clinical study during blood donation

FerroSens GmbH congratulates the researchers and medical doctors from the University Hospital of Munich and the Blood Donation Center of the Bavarian Red Cross in Munich for their recent publication “[Non-Invasive Zinc Protoporphyrin Screening Offers Opportunities for Secondary Prevention of Iron Deficiency in Blood Donors](#)” in the renowned journal “Transfusion Medicine and Hemotherapy” by S. Karger AG, Basel.

The researchers around Dr. Anne Schliemann (LIFE Center, University Hospital Munich) used a prototype of FerroSens’ FIDscreen device for non-invasive screening of iron deficiency on a cohort of 100 blood donors. They could show that FerroSens’ technology is able to measure the iron status marker zinc protoporphyrin IX / heme in red blood cells very accurately during blood donation through the tubing that connects the donor with the blood donation bag.

In addition, the researchers could demonstrate that the zinc protoporphyrin IX / heme ratio identified donors with severe iron deficiency much more accurately than the routinely performed hemoglobin measurement.

“We are delighted that the study confirmed the high accuracy of our technology in measuring the zinc protoporphyrin IX / heme ratio of blood donors. The ease of the measurement together with the immediate result and the low cost per test make FIDscreen an ideal tool for blood donation centers to reliably assess their donors’ iron status. This will allow an improved donor management and contribute significantly to the protection of donors’ health.“ says Dr. Christian Homann, CEO & Founder of FerroSens GmbH and also co-author of the recent publication.

About FerroSens GmbH

FerroSens GmbH (www.ferrosens.de) is a spin-off of the Laser Research Laboratory, an institute of the LIFE Center, at the University Hospital Munich. The company was founded in July 2017 with the main office in Munich (Germany), driven by the WHO’s proclaimed research priority to develop a very cost-effective, portable, reliable instrument to measure the iron parameter Zinc Protoporphyrin. After several years of extensive research and development, clinical studies on close to 1,000 participants showed the high reliability and accuracy of the newly developed non-invasive measurement technique. Since 2021, FerroSens GmbH is a subsidiary of photonamic GmbH & Co. KG, who acquired the majority stakes in FerroSens.

For further information please contact: FerroSens GmbH * info@ferrosens.de *